The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses some of the recent trends in cancer ...

Employers explore innovative strategies at the Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference, ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care ...

Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing ...

Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital, previews key topics of ...

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton ...

Panelists discuss how the needs of older patients with spinal muscular atrophy (SMA) differ from infants, focusing on ...

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond ...

Panelists discuss how spinal muscular atrophy (SMA) progresses over time, affecting motor function differently in older ...

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).